{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:10:43Z","timestamp":1780391443341,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007817","name":"Uniwersytet Rzeszowski","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["KNW-1-108\/N\/6\/K"],"award-info":[{"award-number":["KNW-1-108\/N\/6\/K"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jneuroim.2017.01.019","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:16:31Z","timestamp":1486426591000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Oxidative modifications of blood serum proteins in myasthenia gravis"],"prefix":"10.1016","volume":"305","author":[{"given":"Monika","family":"Adamczyk-Sowa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Bieszczad-Bedrejczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Galiniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Rozmi\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Czy\u017cewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Bartosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Sadowska-Bartosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2017.01.019_bb0005","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1468-1331.2010.03089.x","article-title":"Myasthenia gravis requiring pyridostigmine treatment in a national population cohort","volume":"17","author":"Andersen","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0065-2423(03)37010-6","article-title":"Total antioxidant capacity","volume":"37","author":"Bartosz","year":"2003","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/abio.1996.0292","article-title":"The ferric reducing ability of plasma (FRAP) as a measure of \u201cantioxidant power\u201d: the FRAP assay","volume":"239","author":"Benzie","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0020","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies","author":"Bhatti","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1475-2891-7-29","article-title":"The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk\/benefit profile","volume":"7","author":"Brambilla","year":"2008","journal-title":"Nutr. J."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0035","series-title":"Techniques in Free Radical Research","author":"Diplock","year":"1991"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0040","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000327727","article-title":"Antioxidant status of bilirubin and uric acid in patients with myasthenia gravis","volume":"19","author":"Fuhua","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jat.765","article-title":"Interaction of pyridostigmine and physical stress on antioxidant defense system in skeletal muscle of mice","volume":"21","author":"Jagannathan","year":"2001","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0085","doi-asserted-by":"crossref","first-page":"2483163","DOI":"10.1155\/2016\/2483163","article-title":"Therapeutic strategies for oxidative stress-related cardiovascular diseases: removal of excess reactive oxygen species in adult stem cells","volume":"2016","author":"Kim","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.jneuroim.2017.01.019_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1113\/jphysiol.2011.214007","article-title":"Reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors through a highly conserved cysteine near the intracellular mouth of the channel: implications for diseases that involve oxidative stress","volume":"590","author":"Krishnaswamy","year":"2012","journal-title":"J. Physiol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-065X.1997.tb01032.x","article-title":"Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development","volume":"160","author":"LeMaoult","year":"1997","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0100","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0110","article-title":"Redox-based therapeutics in neurodegenerative disease","author":"McBean","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0115","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/oby.21654","article-title":"Reactive oxygen species and oxidative stress in obesity-recent findings and empirical approaches","volume":"24","author":"McMurray","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcsm.12020","article-title":"Creatinine and myoglobin are poor predictors of anaerobic threshold in colorectal cancer and health","volume":"6","author":"Nyasavajjala","year":"2015","journal-title":"J. Cachex. Sarcopenia Muscle"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0125","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0130","first-page":"453","article-title":"Epidemiology of myasthenia gravis","volume":"134","author":"Pekmezovi\u0107","year":"2006","journal-title":"Srp. Arh. Celok. Lek."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.mad.2008.05.007","article-title":"N-chloroamino acids cause oxidative protein modifications in the erythrocyte membrane","volume":"129","author":"Robaszkiewicz","year":"2008","journal-title":"Mech. Ageing Dev."},{"issue":"5","key":"10.1016\/j.jneuroim.2017.01.019_bb0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neuint.2013.08.009","article-title":"Oxidative modification of serum proteins in multiple sclerosis","volume":"63","author":"Sadowska-Bartosz","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jneuroim.2013.11.005","article-title":"Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment","volume":"266","author":"Sadowska-Bartosz","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0150","doi-asserted-by":"crossref","first-page":"389629","DOI":"10.1155\/2014\/389629","article-title":"Oxidative modification of proteins in pediatric cystic fibrosis with bacterial infections","volume":"2014","author":"Sadowska-Bartosz","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"Suppl. 5","key":"10.1016\/j.jneuroim.2017.01.019_bb0155","first-page":"S40","article-title":"Seronegative myasthenia gravis","volume":"48","author":"Sanders","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0160","first-page":"1","article-title":"Myasthenia gravis","volume":"43","author":"Somnier","year":"1996","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0165","first-page":"366","article-title":"Effect of reactive oxygen species on cholinergic receptor function","volume":"6","author":"Venkatesham","year":"2005","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jnnp-2011-301046","article-title":"Impact commentaries. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"83","author":"Vincent","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0175","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0180","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.freeradbiomed.2013.03.010","article-title":"Role of oxidative stress in physiological albumin glycation: a neglected interaction","volume":"60","author":"Vlassopoulos","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"39","key":"10.1016\/j.jneuroim.2017.01.019_bb0185","doi-asserted-by":"crossref","first-page":"e5000","DOI":"10.1097\/MD.0000000000005000","article-title":"Low serum albumin concentrations are associated with disease severity in patients with myasthenia gravis","volume":"95","author":"Weng","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0190","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ki.1996.186","article-title":"Advanced oxidation protein products as a novel marker of oxidative stress in uremia","volume":"49","author":"Witko-Sarsat","year":"1996","journal-title":"Kidney Int."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0200","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3109\/00207454.2015.1134526","article-title":"Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis","volume":"126","author":"Yang","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0205","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/WNR.0000000000000535","article-title":"Serum uric acid levels in patients with myasthenia gravis are inversely correlated with disability","volume":"27","author":"Yang","year":"2016","journal-title":"Neuroreport"},{"issue":"12","key":"10.1016\/j.jneuroim.2017.01.019_bb0210","doi-asserted-by":"crossref","first-page":"21138","DOI":"10.3390\/molecules201219753","article-title":"Antioxidant phytochemicals for the prevention and treatment of chronic diseases","volume":"20","author":"Zhang","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.jneuroim.2017.01.019_bb0215","first-page":"1287","article-title":"Changes of serum bilirubin and uric acid in patients with myasthenia gravis","volume":"93","author":"Zhou","year":"2013","journal-title":"Zhonghua Yi Xue Za Zhi"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572816304465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572816304465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:30:13Z","timestamp":1759048213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572816304465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":43,"alternative-id":["S0165572816304465"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.01.019","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidative modifications of blood serum proteins in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}